Athanor Capital, LP Arcus Biosciences, Inc. Transaction History

Athanor Capital, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$22.75 - $35.77 $501,705 - $788,835	-22,053 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$26.16 - $41.39 $89,153 - $141,057	-3,408 Reduced 13.39%	22,053 $619,000
Q4 2020 Feb 16, 2021	BUY	$17.0 - $32.36 $246,619 - $469,446	14,507 Added 132.44%	25,461 $661,000
Q3 2020 Nov 16, 2020	BUY	$17.14 - $25.47 $187,751 - $278,998	10,954 New	10,954 $188,000
Q1 2020 May 14, 2020	SELL	$8.78 - $19.28 $230,913 - $507,064	-26,300 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$7.33 - $10.79 $192,779 - $283,777	26,300 New	26,300 $266,000
Q3 2019 Nov 14, 2019	SELL	$6.44 - $10.18 $102,396 - $161,862	-15,900 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$7.29 - $13.38 $115,911 - $212,742	15,900 New	15,900 $126,000

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.14B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.